30 results about "Decreasing heart rate" patented technology

The invention belongs to the technical field of medicines, and provides a propranolol hydrochloride (PPL.HCL) gel which can be externally used for treating infant superficial hemangioma. The propranolol hydrochloride gel is mainly prepared from propranolol hydrochloride, gel matrix, a percutaneous penetration enhancer, a preservative, a humectant and the like. By using the propranolol hydrochloride gel, adverse reactions such as decreased heart rate, cyanosis, airway hyperresponsiveness, shortage of granular leukocytes, diarrhoea, sleep change and blood sugar reduction caused by orally taking propranolol by hemangioma patients can be reduced and even avoided, and the problems that oral dosage is not easy to control, infants inconveniently take medicines and the like are solved.

A method of assessing cardiac ischemia in a subject to provide a measure of cardiovascular health in that subject is described. In general, the method comprises the steps of: (a) collecting a first RR-interval data set from the subject during a stage of gradually increasing heart rate; (b) collecting a second RR-interval data set from the subject during a stage of gradually decreasing heart rate (e.g., after an abrupt stop in exercise; during a stage of gradually decreasing exercise load; etc.); (c) separating fluctuations from a slow trend in the first RR-interval data set; (d) separating fluctuations from a slow trend in the second RR-interval data set; (e) comparing the fluctuations of the first RR-interval data set to the fluctuations of the second RR-interval data set to determine a difference between the fluctuation data sets; and (f) generating from the comparison of step (e) a measure of cardiac ischemia during stimulation in the subject, wherein a greater difference between the first and second data sets indicates greater cardiac ischemia and lesser cardiac or cardiovascular health in the subject.

Use of a composition obtainable by a process comprising fermenting a food material, comprising animal milk or vegetable proteins, with a lactic acid bacterium to obtain a fermented food material which comprises active components with heart rate reducing properties for the manufacture of a product for reducing the heart rate and/or the fluctuations in the heart rate of a mammalian.

The mdx mouse is a model of Duchenne muscular dystrophy. The present invention describes that mdx mice exhibited clinically relevant cardiac phenotypes. A non-invasive method of recording electrocardiograms (ECGs) was used to a study mdx mice (n=15) and control mice (n=15). The mdx mice had significant tachycardia, consistent with observations in patients with muscular dystrophy. Heart-rate was nearly 15% faster in mdx mice than control mice (P<0.01). ECGs revealed significant shortening of the rate-corrected QT interval duration (QTc) in mdx mice compared to control mice (P<0.05). PR interval duration were shorter at baseline in mdx compared to control mice (P<0.05). The muscarinic antagonist atropine significantly increased heart-rate and decreased PR interval duration in C57 mice. Paradoxically, atropine significantly decreased heart-rate and increased PR interval duration in all mdx mice. Pharmacological autonomic blockade and baroreflex sensitivity testing demonstrated an imbalance in autonomic nervous system modulation of heart-rate, with decreased parasympathetic activity and increased sympathetic activity in mdx mice. These electrocardiographic findings in dystrophin-deficient mice provide new bases for diagnosing, understanding, and treating patients with Duchenne muscular dystrophy.

A method of assessing cardiac ischemia in a subject to provide a measure of cardiac or cardiovascular health in that subject is described herein. The method comprises the steps of: (a) collecting a first RR-interval data set from said subject during a stage of gradually increasing heart rate up to a predetermined heart rate of at least 130 beats per minute; (b) collecting a second RR-interval data set from said subject during a stage of gradually decreasing heart rate; (c) comparing said first RR-interval data set to said second RR-interval data set to determine the difference between said data sets; and (d) generating from said comparison of step (c) a measure of cardiac ischemia during stimulation in said subject, wherein a greater difference between said first and second data sets indicates greater cardiac ischemia and lesser cardiac or cardiovascular health in said subject.

The invention discloses a traditional Chinese medicine composition for treating chronic cardiac insufficiency, which is prepared by matching of the traditional Chinese medicines as follows: radix pseudostellariae, radix ophiopogonis, schisandra chinensis, astragalus membranaceus, the root of fangji, pepperweed seed, fructus trichosanthis, monkshood, poria cocos, pseudo-ginseng, bighead atractylodes rhizome, root of common peony, the root of red-rooted salvia, cortex acanthopanacis, Chinese-date, borneol, perillaseed, almond, pinellia ternate, caulis bambusae in taeniam and honey-fried licorice root. Aiming to the pathogenesis of heart failure: depletion of spleen and kidney, insufficient heart yang, blocking of blood vessel, damage of vital energy and blood, evil hydrops and pneuma rushing upwards to the chest, water and pneuma reversing upward and blocking of lung, the traditional Chinese medicine composition, disclosed by the invention, has the treatment rules of benefiting vitality and warming yang, purging the lung of pathogenic fire and promoting diuresis, promoting coronary circulation, improving blood supply of coronary artery, reducing blood pressure, purging the lung of pathogenic fire and regulating qi by alleviation of mental depression, clearing heat and eliminating phlegm, promoting diuresis and alleviating edema, enhancing systole, decreasing heart rate, reducing peripheral resistance, increasing cardiac output, improving microcirculation, relieving smooth muscle spasm and reducing blood platelet gathering rate.

Use of a composition obtainable by a process comprising fermenting a food material, comprising animal milk or vegetable proteins, with a lactic acid bacterium to obtain a fermented food material which comprises active components with heart rate reducing properties for the manufacture of a product for reducing the heart rate and/or the fluctuations in the heart rate of a mammalian.

The invention belongs to the field of pharmaceutical technology. The invention discloses a medicine combination of snakegourd fruit or the extract thereof and pseudoginseng or the extract thereof as well as the preparation method thereof; the invention also discloses the application of the medicine combination on the medicines for treating cerebrovascular diseases and the preparations containing the medicine combination. The effective ingredients of the medicine combination are prepared by the following raw medicines by weight: 200-5000 parts of snakegourd fruit and 100-5000 parts of pseudoginseng, or 4-400 parts of snakegourd fruit extract and 4-250 parts of pseudoginseng extract. The invention can be prepared into any dosage forms acceptable in clinical or pharmacy, and the preferred preparation is oral preparation or injection. The two medicines in the invention have synergistic function and achieve the functions of anti-myocardial ischemia, anti-platelet aggregation, reducing myocardial infarct size and decreasing heart rates together. The invention has significantly increasing curative effect than single administration of snakegourd fruit, the extract thereof, pseudoginseng and the pseudoginseng thereof.

The invention relates to the technical field of medical appliances and particularly relates to an auxiliary device for interventional therapy of a cardiovascular department. The auxiliary device comprises a bleeding arresting device, a monitoring device and a base, wherein the monitoring device is arranged on the base and is fixedly connected with the bleeding arresting device; the monitoring device comprises a monitoring frame, an electrocardiogram monitor and a dynamic blood pressure monitor are arranged at the top of the monitoring frame, the interior of the monitoring frame is partitionedinto a medicine placement groove, an appliance groove and a refuse chute by a plurality of transverse plates, and the medicine placement groove is partitioned into a normal-temperature area and a low-temperature area by a longitudinal plate; and the bleeding arresting device comprises an inverse-L-shaped rod, an electric telescopic rod and a pressing assembly, the inverse-L-shaped rod is fixedly connected with a fixed end of the electric telescopic rod, a telescopic end of the electric telescopic rod is fixedly connected with the pressing assembly, the inverse-L-shaped rod is further connectedwith a universal rod, and the universal rod is fixedly connected with a monitoring camera. According to the auxiliary device for the interventional therapy of the cardiovascular department, remote observation by medical personnel is achieved, an alert can be issued in time after increased heart rate and decreased heart rate phenomena occur, and the medical personnel can conveniently handle in time.

A method of determining the susceptibility to ventricular arrhythmias in a subject, comprises the steps of: (a) collecting (e.g., by surface EKG or intracardiac EKG) at least one QT and DI interval data set from the subject during a stage of gradually increasing heart rate or a stage of gradually decreasing heart rate; (b) determining (e.g., by applying low- and high pass filtering) low-frequency QT-DI interval trends and high-frequency QT-DI fluctuation signals in said at least one QT and DI interval data set; (c) finding a plurality of correlated and anti-correlated portions between said high-frequency QT-DI fluctuation signals; (d) determining corresponding regression lines for said correlated and anti-correlated portions; (e) finding a plurality of (or in some embodiments all) steady state QT-DI points designated by intersections between said low frequency QT-DI trends and said corresponding regression lines; (f) fitting action potential durations computed from a rate dependent reaction-diffusion model to corresponding ones of said steady state QT-DI points to give (i) a model excitation threshold and (ii) a minimal level of refractoriness at a plurality of (or in some embodiments all of) said steady state QT-DI points; (g) at the steady state QT-DI point corresponding to the highest heart rate in said QT and DI interval data set, determining the difference between said minimal level of refractoriness and a model critical excitation threshold for a stable solitary pulse corresponding to the rate dependent reaction diffusion model of step (f) to give a reserve of refractoriness (RoR); (h) fitting action potential durations computed from a rate dependent reaction-diffusion model to said correlated and anti-correlated portions to give a rate of adaptation of each model excitation threshold to a corresponding steady state value at a plurality of (or in some embodiments all of) said steady state QT-DI points; (i) at the steady state QT-DI point corresponding to the highest heart rate in said QT and DI interval data set, determining the inverse of said rate of adaptation to give a reserve of memory (RoM); (j) combining said reserve of refractoriness (RoR) and said reserve of memory (RoM) to produce a metric of stability-of-propagation reserve (SoPR) in said subject, a higher value of SoPR indicating lower susceptibility to ventricular arrhythmias in said subject. Systems and apparatus for carrying out the method are also described.

The present invention addresses the problem of providing an agent for decreasing heart rate having fewer side effects, or a novel agent for suppressing an increase in heart rate during exercise. The heart rate can be decreased, in particular, palpitation, shortness of breath or fatigue associated with an increased heart rate can be prevented or ameliorated, and the increase in heart rate during exercise can be suppressed by ingesting a preparation containing orotic acid or a salt thereof as an active ingredient.

The invention discloses a steroids non-depolarization muscle relaxant antagonistic pharmaceutical composition. The composition comprises 6-deoxy alpha-amino acid derivative cyclodextrin, metoclopramide, angiotensin II, anhydrous sodium acetate, sodium bisulfate, and citric acid. The 6-deoxy alpha-amino acid derivative cyclodextrin is a main component of the pharmaceutical composition; metoclopramide is an antiemetic, anhydrous sodium acetate and sodium bisulfite are added for assisting, and are co-effected on a dopamine receptor in a medulla oblongata chemoreceptor trigger zone, so that a threshold of the chemoreceptor trigger zone is increased; the angiotensin II is one of vaso-excitor active substances, and whole body arteriole contraction and arterial blood pressure rise can be realized; and the adverse symptoms such as decreased heart rate and drop of blood pressure of the steroids muscle relaxant antagonistic pharmaceutical composition can be effectively solved while in use, the pharmaceutical composition realizes combined action, and the steroids non-depolarization muscle relaxant antagonistic pharmaceutical composition capable of effectively reducing vomit and reducing adverse symptoms such as blood pressure can be provided.

Provided is a composition for lowering heart rate, which contains lactic acid bacteria belonging to the genus Lactobacillus. The heart rate of a subject is reduced by allowing the subject to ingest a composition containing lactic acid bacteria belonging to the genus Lactobacillus.

Methods and systems for non-invasive selective control of blood pressure are described. For example, noninvasive stimulation of the auriculotemporal nerve (on the surface of the ear) facilitates a decrease in blood pressure without a corresponding decrease in heart rate or breathing rate, as occurs in stimulation of the cervical vagus and trigeminal nerves. Such a therapy may be particularly beneficial during hypertensive crises or like events where the body naturally decreases heart rate and breathing rate to compensate for an increased blood pressure.

The invention discloses a method for establishing a pulmonary edema rabbit animal model, belongs to the field of biological model construction, and aims to overcome the defect that in the prior art, complicating respiratory system symptoms are generated by reducing heart rate or other external circulation influences. In order to overcome the defects, according to the technical scheme, a medicament for changing the increase of the lung water content is externally and discontinuously injected into an animal to be experimented, so that the liquid content in pulmonary interstitial substances, pulmonary alveoli and cells is increased, and the model is induced to generate pulmonary edema lesion. Compared with the prior art of an oleic acid injection method, an epinephrine instillation method and a chloroform injection method, in the technical scheme, the medicament is directly perfused into the lung to change the concentration of lung water, so that mutagenesis is realized, the influence of heart rate or other external circulation is avoided, mutagenesis models with complicating respiratory system symptoms are overcome, meanwhile, active substances on the surface of the lung are reserved to the maximum extent (direct internal injection), and the influence of complications on experimental data is reduced.

The vagus nerve and branches of the vagus nerve are stimulated below the laryngeal nerve branch bifurcation in order to induce desired parasympathetic responses, such as decreased heart rate, without also triggering any adverse sympathetic responses. Stimulating surfaces of an open field bipolar electrode are positioned on or inserted through the pleural membrane overlying the vagus nerve at a location having substantially no cardiac sympathetic fibers adjacent to the vagus nerve. The open field bipolar electrodes can be securable-wire, needle, plate, or any other type of electrode suitable for being secured to the pleural membrane using one or more fastening mechanisms. Electrical stimuli are generated by a stimulator connected to the stimulating surfaces of the open field bipolar electrode by one or more leads.